Position in ABBV
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$739,317
+$331,308 QoQ
Shares Held
2,938
+56.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.70%
of 13F equity value
Holder Rank
#2,833
of 4,153 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Lynx Investment Advisory holds $4,458,205 across 7 Drug Manufacturers - General names. ABBV ranks #2 (16.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
59,638 | $1,436,081 | |
| 2 | ABBV |
AbbVie Inc.
This page
|
2,938 | $739,317 | |
| 3 | JNJ |
Johnson & Johnson
|
2,594 | $658,796 | |
| 4 | MRK |
Merck & Co., Inc.
|
4,906 | $630,421 | |
| 5 | AZN |
Astrazeneca PLC
|
2,144 | $406,544 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,540 | $319,212 | |
| 7 | NVS |
Novartis AG
|
1,709 | $267,834 |
All Filings in ABBV
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $739,317 | 2,938 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $408,009 | 1,876 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $458,806 | 2,008 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $463,079 | 2,000 | Shares | Other | 2025-11-06 | |
| 2025-06-30 | $369,940 | 1,993 | Shares | Other | 2025-07-18 | |
| 2025-03-31 | $412,753 | 1,970 | Shares | Other | 2025-06-16 | |
| 2024-12-31 | $348,113 | 1,959 | Shares | Other | 2025-02-11 | |
| 2024-09-30 | $337,887 | 1,711 | Shares | Other | 2024-11-04 | |
| 2024-06-30 | $276,146 | 1,610 | Shares | Other | 2024-07-09 | |
| No filing history on record for this holder in this stock. | ||||||